SOLIDARITY clinical trial

SOLIDARITY clinical trial
Name	SOLIDARITY trial
Sponsor	World Health Organization
Phase	Multinational adaptive randomized trial
Start date	2020
Status	Completed

SOLIDARITY clinical trial

The SOLIDARITY clinical trial was a multinational adaptive randomized trial initiated in 2020 by the World Health Organization in response to the COVID-19 pandemic. It enrolled thousands of participants across dozens of countries coordinated with national health authorities such as China-affiliated sites, networks in Italy, Spain, and centers in Brazil and South Africa, aiming to rapidly assess repurposed antiviral and immunomodulatory agents. The trial sought pragmatic, large-scale evidence comparable to efforts like the RECOVERY trial and was conducted alongside initiatives by organizations such as the European Medicines Agency, the U.S. Food and Drug Administration, and the Wellcome Trust.

Background

The trial emerged amid global urgency following the declaration of the COVID-19 pandemic by the World Health Organization and during crises in cities like Wuhan and Lombardy. Convened with input from agencies including the Coalition for Epidemic Preparedness Innovations and the Bill & Melinda Gates Foundation, it reflected coordinated responses similar to historical public-health studies after outbreaks like the 1918 influenza pandemic and responses coordinated by the Centers for Disease Control and Prevention and the National Institutes of Health. Political and scientific leaders such as representatives from Brazilian Ministry of Health and delegations from South Africa participated, mirroring multinational trials like the SOLSTICE programs and collaborations seen in trials sponsored by the European Commission and the United Nations.

Trial design and methodology

SOLIDARITY used an adaptive, open-label design overseen by a global data safety monitoring board with methodology elements inspired by platform trials such as RECOVERY and by guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Randomization schemes connected hospitals in networks coordinated by ministries in countries including India, Argentina, and Mexico. Data harmonization leveraged standards from the World Health Organization and interoperated with registries overseen by the European Medicines Agency and national regulatory authorities like the U.S. Food and Drug Administration. The protocol emphasized rapid enrollment, pragmatic endpoints (in-hospital mortality, ventilation initiation), and interim analyses influenced by precedent trials such as those for Ebola virus epidemic in West Africa therapeutics.

Treatments evaluated

The trial initially evaluated repurposed agents including remdesivir, hydroxychloroquine, lopinavir, and combinations containing ritonavir. Later arms considered adjunctive options resembling interventions tested in other studies like corticosteroids evaluated in RECOVERY (e.g., dexamethasone), and interferons analogous to compounds previously trialed during Middle East respiratory syndrome research. Drug selection reflected availability and prior in vitro or clinical signals from institutions such as National Institute of Allergy and Infectious Diseases and pharmaceutical companies including Gilead Sciences. Decisions to add or discontinue arms were informed by interim results and regulatory statements from bodies such as the European Medicines Agency and the U.S. Food and Drug Administration.

Results and outcomes

Interim and final analyses reported by the coordinating bodies concluded that several evaluated agents—hydroxychloroquine, lopinavir/ritonavir, and interferon beta-1a in some comparisons—did not significantly reduce overall mortality, initiation of ventilation, or duration of hospital stay in broad hospitalized populations. Findings were published in major journals and disseminated through organizations such as the World Health Organization and echoed by parallel results from the RECOVERY trial and trials overseen by the National Institutes of Health. The remdesivir arm produced mixed signals across different analyses, prompting regulatory actions by agencies including the U.S. Food and Drug Administration and the European Medicines Agency to consider conditional authorizations and label updates based on aggregated evidence from SOLIDARITY and trials by Gilead Sciences.

Safety and adverse events

Safety monitoring identified adverse events consistent with known profiles from prior use in contexts such as HIV/AIDS and malaria care—for example, cardiac arrhythmias with hydroxychloroquine and gastrointestinal or hepatic effects with protease inhibitors like lopinavir/ritonavir. Global pharmacovigilance efforts coordinated with systems in United Kingdom, United States, and European Union regulatory agencies documented signals that informed discontinuation decisions. Data safety monitoring processes mirrored standards set by the International Council for Harmonisation and experience from trials during the Ebola virus epidemic in West Africa.

Criticism and controversies

SOLIDARITY faced debate over its open-label design and selection of endpoints, drawing criticism from investigators and commentators associated with institutions like Johns Hopkins University and Imperial College London who advocated for blinding and placebo control similar to trials run by the National Institutes of Health. Political controversies arose as national policymakers in countries such as Brazil and India navigated trial participation amid divergent public messaging from leaders including those in Brazilian government and United States administrations. Discourse in scientific media and platforms involving journals like The Lancet and New England Journal of Medicine highlighted tensions between rapid pragmatic trials and traditional randomized controlled trial norms.

Impact and legacy

SOLIDARITY influenced global therapeutic guidance from the World Health Organization and national bodies including the Centers for Disease Control and Prevention and shaped regulatory decisions by the European Medicines Agency and the U.S. Food and Drug Administration. Its pragmatic, multinational model informed subsequent platform trials and preparedness frameworks championed by organizations such as the Coalition for Epidemic Preparedness Innovations and the Wellcome Trust. The trial’s outcomes contributed to evidence synthesis used by guideline panels like those convened by the World Health Organization and academic consortia at Oxford University and Harvard University, and left a methodological legacy for rapid-response clinical research deployed during future outbreaks.

Category:Clinical trials